CY1118655T1 - Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης - Google Patents

Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Info

Publication number
CY1118655T1
CY1118655T1 CY20171100070T CY171100070T CY1118655T1 CY 1118655 T1 CY1118655 T1 CY 1118655T1 CY 20171100070 T CY20171100070 T CY 20171100070T CY 171100070 T CY171100070 T CY 171100070T CY 1118655 T1 CY1118655 T1 CY 1118655T1
Authority
CY
Cyprus
Prior art keywords
treatment
pyrimidinodiamines
athleticosis
prevention
compounds
Prior art date
Application number
CY20171100070T
Other languages
English (en)
Inventor
Esteban Masuda
Jochen Schmitz
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of CY1118655T1 publication Critical patent/CY1118655T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Περιγράφονται νέες μέθοδοι και συνθέσεις για την πρόληψη και τη θεραπεία των μορφών αθηροσκλήρωσης με ενώσεις 2,4-πυριμιδινοαμίνης. Επίσης αποκαλύπτεται η επίχριση προσθετικών συσκευών, όπως στεντ, με τις ενώσεις της εφεύρεσης για την πρόληψη και/ή θεραπεία της επαναστένωσης.
CY20171100070T 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης CY1118655T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22
PCT/US2009/034718 WO2009105675A1 (en) 2008-02-22 2009-02-20 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1118655T1 true CY1118655T1 (el) 2017-07-12

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100070T CY1118655T1 (el) 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Country Status (20)

Country Link
US (1) US8530466B2 (el)
EP (1) EP2252300B1 (el)
JP (1) JP5586482B2 (el)
KR (1) KR101614555B1 (el)
CN (1) CN102014917A (el)
AU (1) AU2009215430B2 (el)
BR (1) BRPI0907724B8 (el)
CA (1) CA2715962C (el)
CY (1) CY1118655T1 (el)
DK (1) DK2252300T3 (el)
ES (1) ES2610880T3 (el)
HR (1) HRP20170050T1 (el)
HU (1) HUE030307T2 (el)
LT (1) LT2252300T (el)
MX (1) MX2010009159A (el)
PL (1) PL2252300T3 (el)
PT (1) PT2252300T (el)
RU (1) RU2490015C2 (el)
SI (1) SI2252300T1 (el)
WO (1) WO2009105675A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2516434B1 (en) 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
PH12013500246A1 (en) 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
SMT201900071T1 (it) 2011-07-28 2019-02-28 Rigel Pharmaceuticals Inc Nuove formulazioni di (trimetossifenilammino)pirimidinile
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016020828A1 (en) * 2014-08-08 2016-02-11 Raffaele Migliaccio Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
CN121226395A (zh) * 2025-09-19 2025-12-30 南京医科大学 抑制nek7的药物在制备抑制平滑肌细胞表型转化改善内膜新生药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429078T2 (de) * 1993-10-01 2002-07-11 Novartis Ag, Basel Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
AU5438299A (en) * 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU2002316421B2 (en) * 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
CA2473910C (en) * 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
JP2005526765A (ja) * 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
US7449458B2 (en) * 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
DE102005016634A1 (de) * 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007257701A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺

Also Published As

Publication number Publication date
KR20100126422A (ko) 2010-12-01
JP5586482B2 (ja) 2014-09-10
EP2252300A1 (en) 2010-11-24
HUE030307T2 (en) 2017-04-28
PT2252300T (pt) 2017-01-06
CA2715962A1 (en) 2009-08-27
KR101614555B1 (ko) 2016-04-21
RU2010138899A (ru) 2012-03-27
US20110046126A1 (en) 2011-02-24
WO2009105675A1 (en) 2009-08-27
PL2252300T3 (pl) 2017-04-28
RU2490015C2 (ru) 2013-08-20
BRPI0907724B1 (pt) 2019-12-17
HRP20170050T1 (hr) 2017-03-10
MX2010009159A (es) 2010-09-14
ES2610880T3 (es) 2017-05-03
EP2252300B1 (en) 2016-10-19
HK1150555A1 (en) 2012-01-06
DK2252300T3 (en) 2017-02-06
JP2011513230A (ja) 2011-04-28
AU2009215430A1 (en) 2009-08-27
US8530466B2 (en) 2013-09-10
SI2252300T1 (sl) 2017-04-26
AU2009215430B2 (en) 2015-02-12
CN102014917A (zh) 2011-04-13
CA2715962C (en) 2017-03-07
LT2252300T (lt) 2017-02-10
BRPI0907724B8 (pt) 2021-05-25
BRPI0907724A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2010009159A (es) Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
CY1115952T1 (el) Παραγωγα πυραζολο πυριδινης σαν αναστολεις της οξειδασης nadρη
CY1121824T1 (el) Μεθοδοι και συνθεσεις για προληψη και ανακουφιση μυικων κραμπων και για αποκατασταση απο νευρομυικη ευερεθιστικοτητα και κοπωση μετα απο ασκηση
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
ATE541597T1 (de) Implantierbare vorrichtung mit sich langsam auflösendem polymer
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
IN2012DN03883A (el)
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1116034T1 (el) 2-ανιλινοβενζιμιδαζολο-6-καρβοξαμιδια ως αντι-φλεγμονωδεις παραγοντες
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA201201608A1 (ru) Солнцезащитная композиция
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
CY1119999T1 (el) Καινοτομος συνθεση για τη θεραπευτικη αντιμετωπιση της κυστικης ινωσης